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Pathologic staging is currently the most important prognostic factor in colon cancer,
although individually this procedure does not provide a complete clinical outcome.
This study aimed to determine the disease-speciﬁc survival of patients with colon can-
cer treated in the Braga Hospital from January 2005 to December 2013, according to the
American Joint Committee on Cancer, 6th edition, and the disease-free survival and disease-
speciﬁc survival of high- and low-risk stage II patients, whether in use, or not, of adjuvant
chemotherapy.
We  obtained a total sample of 578 patients, with 145 and 65 high- and low-risk stage
II  patients, respectively. We  observed a 5-year disease-speciﬁc survival rate of 93%, 27.4%
and  75% for stage IIA, IIB and IIIA patients, respectively, where IIIA and IIB present statis-
tically signiﬁcant differences (p = 0.001). In high-risk stage II patients, disease-free survival
(p  = 0.107) and disease-speciﬁc survival (p = 0.037) were higher in the group submitted to
chemotherapy. In low- risk patients, disease-free survival was higher in the group submitted
to  chemotherapy (p = 0.494), while disease-speciﬁc survival was lower (p = 0.426).
The differences observed between stage IIB and IIIA survival can be explained by the
consensual use of adjuvant chemotherapy in stage IIIA, and by its controversial use in stage
IIB.  Adjuvant chemotherapy showed to be effective only in high-risk stage II patients in
terms of disease-speciﬁc survival.
In the future, other markers, namely molecular ones, may be used to stratify the risk of
stage II patients and determine who will beneﬁt from adjuvant chemotherapy.
©  2015 Sociedade Brasileira de Coloproctologia. Published by Elsevier Editora Ltda. All
rights reserved.
Avaliac¸ão  o  prognóstico  de  pacientes  com  cancer  de  colon  no  estadio  II
r  e  s  u  m  oalavras-chave:
âncer de cólon
stadio II de alto risco e baixo risco
obrevivência livre de doenc¸a
O estadiamento patológico é, atualmente, o fator de prognóstico mais importante do câncer
de  cólon, embora individualmente não preveja totalmente o resultado clínico.
Neste estudo, pretendeu-se determinar a sobrevivência para uma doenc¸a especíﬁca (SDE)
dos  pacientes com câncer de cólon tratados no Hospital de Braga entre janeiro de 2005 e
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Sobrevivência para uma doenc¸a
especíﬁca
dezembro de 2013, de acordo com a 6a edic¸ão da American Joint Committee on Cancer e a
Sobrevivência Livre de Doenc¸a (SLD) e SDE dos doentes em estadio II, classiﬁcados em alto
e  baixo risco, de acordo com a realizac¸ão ou não de quimioterapia adjuvante.
Obtivemos uma amostra total de 578 pacientes, dos quais uma parcela pertencia ao esta-
dio II de alto ou de baixo risco (145 e 65 pacientes, respetivamente). Observamos SDE a 5
anos  de: 93%, 27,4% e 75% para os estadios IIA, IIB e IIIA, respetivamente; IIIA e IIB apresen-
taram diferenc¸as signiﬁcativas (p = 0,001). SLD (p = 0,107) e SDE (p = 0,037) para o estadio II
de  alto risco foram superiores no grupo tratado com quimioterapia. Nos doentes de baixo
risco, SLD foi superior no grupo tratado com quimioterapia (p = 0,494), enquanto que SDE foi
inferior (p = 0,426).
As diferenc¸as de sobrevivência observadas para os estadios IIB e IIIA podem se dever ao
uso controverso da quimioterapia em IIB e ao uso consensual em IIIA. O uso da quimioterapia
adjuvante demonstrou ser efetivo nos doentes em estadio II de alto risco em termos de SDE.
Futuramente, outros marcadores, nomeadamente moleculares, poderão vir a ser uti-
lizados para estratiﬁcar o risco do estadio II e deﬁnir quem se beneﬁciará com o tratamento
adjuvante.
©  2015 Sociedade Brasileira de Coloproctologia. Publicado por Elsevier Editora Ltda.
Todos os direitos reservados.Introduction
The incidence of neoplasms and the associated mortality have
been increasing worldwide.1 In 2012, colorectal cancer (CRC)
was rated third place among neoplasias with the highest inci-
dence (1.4 million cases, 9.7%) and was rated 4th place in terms
of mortality (8.5%) worldwide.2 In Portugal, CRC is rated 2nd
place among neoplasias with highest incidence and mortal-
ity in both men  and women, with an incidence and mortality
of 14.8% and 15.7% in men  and 14.1% and 15.9% in women,
respectively.2 In 2008, in northern Portugal, CRC was the sec-
ond most frequent neoplasia, both in women (15.1%) and men
(18.7%).3
Currently, pathologic staging is the most important progno-
stic factor, although individually this procedure cannot fully
predict the clinical outcome,4–6 and the staging system most
often used is the Tumor-Node-Metastasis (TNM) system of the
American Joint Committee on Cancer (AJCC). As the stage pro-
gresses from I to IV, the overall ﬁve-year survival falls from
values greater than 90% (stage I) to less than 10% (stage IV).
Stages II and III have overall survivals of 70–85% and 25–80%,
respectively.7
In recent decades, the prognosis has been improving,
thanks to factors such as an earlier diagnosis and staging
and treatment advances.8–10 More  recently, the 6th edition of
AJCC11 was revised, and its 7th edition (2010) is currently in
use.12
Thus, staging procedures are useful for proposing the
prognosis; however, T3-4N0 (stage II) patients have a worse
Disease-Speciﬁc Survival (DSS) (87.5%, 79.6%, 58.4%) versus
T1-2N1a (stage III) patients (90.7%).13 This suggests that other
factors contribute to the prognosis of the patients, namely,
the presence of perforation or intestinal obstruction at the
time of diagnosis, preoperative increase in carcinoembryonic
antigen, low histological differentiation, presence of lympho-
vascular and perineural invasion, and resection of less than
12 lymph nodes together with the surgical specimen.14,15The higher DSS of T1-2N1a patients with respect to stage II
can also be justiﬁed by the fact that, for stage III patients,
the beneﬁts of adjuvant chemotherapy are established; on
the other hand, the use of this therapy still remains con-
troversial for stage II patients.16,17 This controversy is well
documented in a literature review conducted by André et al.,18
in which several studies document absence of beneﬁt with
adjuvant chemotherapy for overall and disease-free survival
in stage II patients, including the study International Multi-
centre Pooled Analysis of B2 of Cancer Trials (IMPACT B2),19 the
meta-analysis by Figueiredo et al.20 and a meta-analysis pub-
lished by the Mayo Clinic.21 On the other hand, the analysis of
the National Surgical Adjuvant Breast and Bowel Project Adju-
vant Studies (NSABP) (21), a Japanese meta-analysis22 and the
study Quick and Simple and Reliable Study (QUASAR)23 found
beneﬁts in its use, and NSABP noted that adjuvant chemother-
apy reduces extensively the risk of recurrence.21 The group
Adjuvant Rectal Cancer Endpoints (ACCENT) also found bene-
ﬁt with the use of adjuvant chemotherapy in stage II patients,
in terms of survival.24
According to the National Cancer Institute, the decision to
introduce adjuvant chemotherapy for stage II patients must
be made individually; presently, this procedure is not suitable
for most patients, unless they are included in clinical trials.25
According to the European Consensus of 2014 for the
European Registration of Cancer Care (EURECCA), one should
consider the use of adjuvant chemotherapy in high-risk stage
II patients, including those with T4 tumors, with less than
10 lymph nodes examined, presenting venous and lymphatic
invasion, with poor tumor differentiation, and with tumor
perforation.26 The same criteria are used by the American
Society of Clinical Oncology (ASCO) to identify stage II patients
who should undergo adjuvant chemotherapy, with the excep-
tion that ASCO consider a minimum of 12 nodes instead of
those 10 nodes mentioned in the EURECCA consensus, impos-
ing also the presence of bowel obstruction as one of the
selection criteria.27
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The literature is very controversial on the role of adjuvant
hemotherapy in stage II patients; thus, the aim of this study
s to carry out an assessment on this topic in patients treated
t the Braga Hospital.
aterials  and  methods
he target population for the study consisted of patients with
olon adenocarcinoma treated at the Braga Hospital between
anuary 1, 2005, and December 31, 2013. A sample of conve-
ience, consisting of 578 patients, was elaborated based on
he following inclusion/exclusion criteria.
Inclusion criteria:  Postoperative histological diagnosis of
olon adenocarcinoma in patients who  underwent curative
urgical resection at the Braga Hospital between January 1,
005, and December 31, 2013.
Exclusion criteria:  Patients with a different histological
iagnosis from the mentioned above; patients with rec-
al adenocarcinoma; patients who died in the ﬁrst 30 days
fter surgery; patients who underwent primary therapy;
atients with a personal history of CRC and hereditary
yndromes.
ethodology
 prospective analysis of the Coloproctology Unit database at
he Braga Hospital was held, consisting of clinical, patholog-
cal and follow-up data. Subsequently, stage II patients were
ivided into two groups: of low-and high-risk, based on criteria
eﬁned by the EURECCA consensus.26
This project was approved by the Ethics Committee for
ealth and by the Ethics Subcommittee for Life and Health
ciences of the Braga Hospital.
tatistical  analysis
he collected data were analyzed using the Statistical Package
or Social Sciences (SPSS) software, version 19.0 (SPSS Inc.,
hicago, IL, USA).
For the total sample of patients, a descriptive analysis of
ariables was performed. Next, Kaplan–Meier curves for DSS
nd for the different stages of AJCC (6th edition) were obtained.
he Log-Rank test (Mantel–Cox), with a signiﬁcance set in 0.05,
as applied to detect differences of DSS between groups. Five-
ear DSS was determined for all groups.
Kaplan–Meier curves for DFS and DSS were obtained for
igh- and low-risk stage II patients, according to the use or
on-use of adjuvant chemotherapy.
The Log-Rank test (Mantel–Cox), with a signiﬁcance set in
.05, was applied to detect differences of DSS and DFS among
he group treated with adjuvant chemotherapy versus non-
reated group. Five-year DSS and DFS were determined for all
roups.
DFS is deﬁned as the period from surgery to recurrence of
isease, and DSS as the period from surgery until the patient’s
ied from the disease.;3 5(4):203–211 205
Results
Sample  characterization
The study population consists of 578 individuals; 61.9%
(n = 358) males and 38.1% (n = 220) females. The mean age at
the time of surgery was 67.9 years.
As regards to the pathological staging, the study popu-
lation had the following characteristics: 47.8% (n = 276) had
nodal metastases and 14.4% (n = 83) were already with distant
metastases.
As for the administration of adjuvant chemotherapy, this
procedure was performed in 54.7% (n = 316) of patients, while
34.4% (n = 199) were not treated. During follow-up, 75.8%
(n = 375) showed no recurrence of the disease; on the other
hand, in 18.4% (n = 91) there was a recurrence. Overall, 19.9%
(n = 115) died from the disease.
DSS  analysis,  according  to  AJCC  (6th  edition)
The mean DSS was calculated for the different stages, as
follows: Stage I, 113.1 months (95% conﬁdence interval [CI]:
109.5–116.7); stage IIA, 107.2 months (95% CI: 103.3–111.1);
stage IIB, 46.4 months (95% CI: 17.9–74.9); stage IIIA, 93.8
months (95% CI: 67.9–119.6); stage IIIB, 89.7 months (95% CI:
81.2–98.2); stage IIIC, 63.3 months (95% CI: 48.5–78.1); and stage
IV, 43.7 months (95% CI: 33.3–54.1). The mean DSS of this
sample is 90.6 months (95% CI: 86.7–94.5). In paired compar-
isons between stages, statistically signiﬁcant differences for
DSS have been found in most cases, where the Log-Rank test
obtained a p-value lower than 0.05, except between stages I
and IIA (Log-Rank = 2.896; p = 0089); I and IIIA (Log-Rank = 3.658;
p = 0.056); IIA and IIIA (Log-Rank = 0.109; p = 0741); IIB and
IIIC (Log-Rank = 1.232; p = 0.267); IIB and IV (Log-Rank = 0.036;
p = 0.850); and IIIA and IIIB (Log-Rank = 1.749; p = 0.186).
With regard to the ﬁve-year DSS by stage, we  observed
100% for stage I; 93% (95% CI: 88.5–97.5%) for stage IIA; 27.4%
(95% CI: 0–59.2%) for stage IIB; 75% (95% CI: 32.5–100%) for
stage IIIA; 72.5% (95% CI: 62.3–82.7%) for stage IIIB; 51.1% (95%
CI: 33.9–68.3%) for stage IIIC; and 28.3% (95% CI: 16.3–40.2%)
for stage IV. The ﬁve-year DSS sample is 75.4% (95% CI:
71.1–79.7%). The survival curves are shown in Fig. 1.
Low-risk  stage  II  patients’  group  assessment
The low-risk group consisted of 65 individuals, 60% (n = 39)
male and 40% (n = 26) female. The mean age at diagnosis was
69.9 years.
As for the administration of adjuvant chemotherapy, this
procedure was performed in 44.6% (n = 29) of patients, while
40% (n = 26) were not thus treated.
During the follow-up, 13.8% (n = 9) presented recurrence of
the disease and 3.1% (n = 2) died from the disease. All patients
who died belonged to the group that underwent adjuvant
chemotherapy.We compared the prognosis for low-risk stage II patients
who underwent adjuvant chemotherapy versus those not thus
treated. The mean DFS of low-risk stage II group was 84.2
months (95% CI: 73–95.4). The mean DFS for the low-risk group
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Fig. 1 – DSS for each stage of AJCC (6th edition).who  underwent adjuvant chemotherapy was 82.4 months
(95% CI: 68.1–96.7), and for the group not thus treated, the
mean DFS was 59.2 months (95% CI: 54.1–64.3). The DFS differ-
ences between the two groups are not statistically signiﬁcant
(Log-Rank = 0.468; p = 0.494).
The mean ﬁve-year DFS for the low-risk group was 71.3%
(95% CI: 52.1–90.5%); for the group that underwent chemother-
apy, the mean ﬁve-year DFS was 71.8% (95% CI: 51.6–92%)
versus 63.8% (95% CI: 12.4–100%) for the group not thus treated.
The survival curves are shown in Fig. 2(A and B).
The mean DSS for the low-risk stage II group was 98.9
months (95% CI: 90.9–106.9). The differences of DSS between
the group that underwent chemotherapy versus the group not
thus treated was not statistically signiﬁcant (Log-Rank = 0634,
p = 0.426).
The mean ﬁve-year DSS for the low-risk group was 96%
(95% CI: 88.4–100%); 93.8% (95% CI: 81.8–100%) for the group
that underwent chemotherapy versus 100% for the group not
thus treated. The survival curves are shown in Fig. 3(A and B).
High-risk  group
The high-risk group consisted of 145 subjects, 62.1% (n = 90)
males and 37.9% (n = 55) females. The mean age at diagnosis
was 70.9 years.
As for the administration of adjuvant chemotherapy, this
was carried out in 49% (n = 71) of patients, while 35.9% (n = 52)
did not undergo this procedure.
During the follow-up, 17.2% (n = 25) of patients had disease
recurrence and 12.4% (n = 18) died from the disease.
The prognosis for high-risk patients who underwent adju-
vant chemotherapy was compared to that for those who were
not thus treated. The mean DFS for the high-risk stage II group
was 96.5 months (95% CI: 89.9–103). In the group that under-
went chemotherapy, the mean DFS was 98.8 months (95%CI: 90.3–107.2) versus 85 months (95% CI: 72.1–97.9) in the
group not thus treated. The differences in DFS  between the
two groups are not statistically signiﬁcant (Log-Rank = 2.598;
p = 0.107).
The ﬁve-year DFS for high-risk stage II group was 80.5%
(95% CI: 73.4–87.6%), with 83.4% (95% CI: 74.4–92.4%) for those
patients who underwent chemotherapy and 68.8% (95% CI:
54.1–83.5%) for those not thus treated. The survival curves are
shown in Fig. 4(A and B).
The mean DSS for high-risk stage II group was 102.8 months
(95% CI: 97.5–108). Patients who underwent chemotherapy
presented a mean DSS of 105.5 months (95% CI: 99.3–111.8)
and those whose procedure was not carried out the mean
DSS was 90.3 months (95% CI: 78.4–102.2). The differences in
DSS between the two groups are statistically signiﬁcant (Log-
Rank = 4.337; p = 0.037).
The mean ﬁve-year DSS in high-risk stage II patients was
87.9% (95% CI: 81.8–94%); in patients undergoing chemother-
apy this value was 88.9% (95% CI: 81.1–96.7%); and in patients
not submitted to chemotherapy this value was 82.5% (95% CI:
70.3–94.7%).
The survival curves are shown in Fig. 5(A and B).
Discussion
One of the goals of our study was to determine DSS of patients
with colon cancer, according to the 6th edition of the AJCC.
The ﬁve-year DSS of our patients was as follows: stage I –
100%, IIA – 93%, IIB – 27.4%, IIIA – 75%, IIIB – 72.5%, IIIC
– 51.1%; and IV – 28.3%. We found that the ﬁve-year DSS
in our sample decreases with the progression of the stage,
except for stage IIB that has the lowest survival of all, but
with no statistically signiﬁcant difference versus stages IIIC
and IV. This later ﬁnding contradicts the literature,7 although
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Fig. 2 – (A) DFS of low-risk stage II patients; (B) DFS according to the administration of chemotherapy, for low-risk stage II
patients.
s
b
b
r
o
s
h
t
p
u
t
pimilar values are also observed.17 The insufﬁcient num-
er of individuals in our sample for each stage may have
een one factor responsible for the differences between our
esults and the literature ﬁndings, and also by the absence
f statistically signiﬁcant differences in DSS between some
tages.
In our study, as in other studies reviewed, DSS for IIIA is
igher than to DSS for IIB (p = 0.001).17 Although care should be
aken in interpreting this data (in the face of the low number of
atients with stage IIB), this fact may be due to the consensual
se of adjuvant chemotherapy in patients in stage III, and, on
he other hand, to the controversial use of this procedure in
atients with stage II.16,17Reviewing the literature, we note that the use of adju-
vant chemotherapy in patients in stage II is not consensual,16
as several studies documenting the lack of beneﬁt were
published,18–21 while other studies show evidence of gain with
this procedure,21–24 stressing that only small absolute bene-
ﬁts will be obtained in the face of the risk of overtreatment,
including toxicity.23 Thus, the use of adjuvant chemotherapy
in patients with stage II will be only recommended for high-
risk patients.26,27
For high-risk stage II patients, the means of DFS and DSS
were higher in the group that underwent adjuvant chemother-
apy (98.8 and 105.5 months, respectively) versus the group
not treated (85 and 90.3 months, respectively), and ﬁve-year
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Fig. 3 – (A) DSS of low-risk stage II patients; (B) DSS according to the administration of chemotherapy, for low-risk stage II
patients.DFS and DSS were also higher in the group that under-
went adjuvant chemotherapy (83.4% and 88.9%, respectively)
compared with the non-treated group (68.8% and 82.5%,
respectively). DFS values yielded not statistically signiﬁcant
results (p = 0.107); on the other hand, the results obtained for
DSS were statistically signiﬁcant (p = 0.037). These data are
consistent with several studies showing the beneﬁt of the
adjuvant chemotherapy in terms of overall survival and DFS.
Grande et al.28 studied high-risk stage IIA patients, having
found higher overall survivals and ﬁve-year DFS in patients
receiving adjuvant chemotherapy, compared to patients sub-
mitted only to surgery. In the MOSAIC study, their authorsdemonstrated that the use of FOLFOX4 reduced the relative
risk of relapse in 28% of high-risk stage II patients.29 NSABP21
showed some beneﬁt with the use of chemotherapy in terms of
survival for stage II patients with a poor prognosis (T4 tumors,
obstruction, perforation). In the study by Kumar et al.,30 these
authors found statistically signiﬁcant beneﬁts of the adjuvant
chemotherapy in terms of DFS and DSS only for patients with
T4 tumors.
For low-risk stage II patients, the mean DFS is higher in
the group that underwent chemotherapy (82.4 months) com-
pared to the group not thus treated (59.2 months). This also
occurred with the mean ﬁve-year DFS (71.8% vs 63.8%), but
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Fig. 4 – (A) DFS of high-risk stage II patients; (B) DFS according to the administration of chemotherapy, for high-risk stage II
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whe differences between groups were not statistically signif-
cant (p = 0.494). The ﬁve-year DSS was 100% for the group
hat did not receive chemotherapy, and 93.8% for the group
hus treated; but caution is needed in interpreting these
ata, taking into account the small number of events (two)
n this patient group. The differences between groups were
ot statistically signiﬁcant (p = 0.426). Grande et al.28 found
tatistically signiﬁcant differences in favor of the use of
hemotherapy in terms of overall survival and of ﬁve-year DFS,
owever Kumar et al.30 found that the use of chemotherapy
as associated with worse DFS and DSS.In our study the use of adjuvant chemotherapy, with
respect to DSS, was only effective in high-risk stage II patients.
Our study has its limitations: the small sample size compared
to other studies, the high percentage of censored individuals
and the lack of randomized groups. To study low-  and high-
risk stage II patients, we used samples of 55 and 123 patients,
respectively. Patients were divided according to whether adju-
vant chemotherapy was administered or not, and it was not
taken into account the strength of the dose administered to
each patient and the heterogeneity within each group, such
as comorbidities.
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Fig. 5 – (A) DSS of high-risk stage II patients; (B) DSS according to the administration of chemotherapy, for high-risk stage II
patients.
Conclusion
Pathologic staging is currently the main indicator of colon
cancer prognosis, although individually this procedure cannot
fully predict clinical outcome. According to the literature, we
found in our sample that stage IIIA patients present higher
DSS versus stage IIB patients (p = 0.001), although one must
bear in mind the small number of patients in these two stages,
and this can also justify why the absolute values of ﬁve-
year DSS differ from those described in the literature. One
can justify this situation with the consensual use of adjuvantchemotherapy in stage III patients, and its controversial use
in stage II patients. For the remaining stages, the values are
close to those described in the literature.
In our study, the use of adjuvant chemotherapy was
effective for DSS only in high-risk stage II patients. For the
remaining parameters evaluated, the results were controver-
sial and not statistically signiﬁcant, which could be related to
the small number of patients, to censorship and to the absence
of randomized study groups.
The controversy surrounding adjuvant chemotherapy
administration to high- and low-risk stage II patients suggests
the possibility of new markers, including molecular ones, to be
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sed to stratify the stage II risk and to deﬁne who will beneﬁt
rom adjuvant therapy.
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